Login / Signup

Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies.

Bradley Alexander McGregorMatthew T CampbellWanling XieSubrina FarahMehmet Asim BilenAndrew L SchmidtGuru P SonpavdeKerry L KilbridgeAtish D ChoudhuryAmir MortazaviAmishi Y ShahAradhana M VenkatesanGlenn J BubleyArlene O Siefker-RadtkeRana R McKayToni K Choueiri
Published in: Cancer (2020)
Patients with rare cancers are often excluded from studies and have limited treatment options. Fifty-five patients with rare tumors of the genitourinary system were enrolled from multiple sites and were treated with nivolumab and ipilimumab, a regimen used for kidney cancer. The regimen showed activity in some patients, particularly those with bladder or upper tract cancers of unusual or variant histology; 37% of those patients responded to therapy. Additional studies are ongoing to better determine who benefits the most from this combination.
Keyphrases